Abstract
The structure-activity relationships of azetidine-based DPP IV inhibitors will be discussed in detail in the following review. The azetidine-based DPP IV inhibitors can be divided into three main subtypes, the 2-cyanoazetidines, 3-fluoroazetidines and 2-ketoazetidines. These subtypes have been explored and structure-activity relationships have been established by several groups. Several compounds within each of these subtypes display sub micromolar potency against DPP IV. The most potent cyanoazetidines and ketoazetidines have large, hydrophobic amino acid groups bound to the azetidine nitrogen and display activities below 100nM. DPP IV inhibition is not sensitive to stereochemistry at the 2- position as both 2-(R)- and 2-(S)-cyano and -keto azetidines display similar inhibitory potencies. While these “warhead”- based cyano- and ketoazetidines have the potential for covalent, bond-forming inhibition, they can also react to internally cyclize into inactive ketopiperazines and dihydroketopyrazine. Thus, chemical instability was also explored for compounds in these two subtypes and certain members of the cyanoazetidine series display aqueous stability comparable to the closely related cyanopyrrolidines. Select 3-fluoroazetidines also display inhibitory potencies below 1μM without the propensity for cyclization and chemical instability associated with the other subseries.
Keywords: Pyrrolidine Based DPP IV Inhibitors, ketone-based DPP IV inhibitors, Cyanopyrrolidine, fluoroazetidines, ketopyrrolidines
Current Topics in Medicinal Chemistry
Title: Azetidine-Based Inhibitors of Dipeptidyl Peptidase IV (DPP IV)
Volume: 7 Issue: 6
Author(s): Dana Ferraris, Sergei Belyakov, Weixing Li, Eddie Oliver, Yao-Sen Ko, David Calvin, Susan Lautar, Bert Thomas and Camilo Rojas
Affiliation:
Keywords: Pyrrolidine Based DPP IV Inhibitors, ketone-based DPP IV inhibitors, Cyanopyrrolidine, fluoroazetidines, ketopyrrolidines
Abstract: The structure-activity relationships of azetidine-based DPP IV inhibitors will be discussed in detail in the following review. The azetidine-based DPP IV inhibitors can be divided into three main subtypes, the 2-cyanoazetidines, 3-fluoroazetidines and 2-ketoazetidines. These subtypes have been explored and structure-activity relationships have been established by several groups. Several compounds within each of these subtypes display sub micromolar potency against DPP IV. The most potent cyanoazetidines and ketoazetidines have large, hydrophobic amino acid groups bound to the azetidine nitrogen and display activities below 100nM. DPP IV inhibition is not sensitive to stereochemistry at the 2- position as both 2-(R)- and 2-(S)-cyano and -keto azetidines display similar inhibitory potencies. While these “warhead”- based cyano- and ketoazetidines have the potential for covalent, bond-forming inhibition, they can also react to internally cyclize into inactive ketopiperazines and dihydroketopyrazine. Thus, chemical instability was also explored for compounds in these two subtypes and certain members of the cyanoazetidine series display aqueous stability comparable to the closely related cyanopyrrolidines. Select 3-fluoroazetidines also display inhibitory potencies below 1μM without the propensity for cyclization and chemical instability associated with the other subseries.
Export Options
About this article
Cite this article as:
Ferraris Dana, Belyakov Sergei, Li Weixing, Oliver Eddie, Ko Yao-Sen, Calvin David, Lautar Susan, Thomas Bert and Rojas Camilo, Azetidine-Based Inhibitors of Dipeptidyl Peptidase IV (DPP IV), Current Topics in Medicinal Chemistry 2007; 7 (6) . https://dx.doi.org/10.2174/156802607780090993
DOI https://dx.doi.org/10.2174/156802607780090993 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Roles of Parathyroid Hormone and Calcitonin in Bone Remodeling: Prospects for Novel Therapeutics
Endocrine, Metabolic & Immune Disorders - Drug Targets Structural Alterations of the Retinal Microcirculation in the “Prehypertensive” High- Normal Blood Pressure State
Current Pharmaceutical Design The Nun Study: Risk Factors for Pathology and Clinical-Pathologic Correlations
Current Alzheimer Research Cancer Vaccines in Phase II/III Clinical Trials: State of the Art and Future Perspectives
Current Cancer Drug Targets Obstructive Sleep Apnea and Autoimmune Rheumatic Disease: Is there Any Link?
Inflammation & Allergy - Drug Targets (Discontinued) Preliminary Studies on Optimization of Anti-Parkinson Drug Loaded Lipid Nanoparticles Enriched Hydrogel Formulations for Management of Parkinson’s Disease
Current Nanomedicine Regulation of MET Receptor Signaling by SOCS1 and its Implications for Hepatocellular Carcinoma
Current Pharmaceutical Design CD36 as a Therapeutic Target for Endothelial Dysfunction in Stroke
Current Pharmaceutical Design Dissecting the Diverse Actions of Pro- and Mature Neurotrophins
Current Alzheimer Research Quetiapine Fumarate Loaded Mucoadhesive Nanoemulsion: Formulation, Optimization & Brain Delivery via Intranasal Administration
Drug Delivery Letters Toxicities by Herbal Medicines with Emphasis to Traditional Chinese Medicine
Current Drug Metabolism The Association of <i>CYP2D6*4</i> and <i>POR*28</i> Polymorphisms on Mirtazapine Plasma Level in Subjects with Major Depressive Disorder and Anxiety Disorders
Combinatorial Chemistry & High Throughput Screening Advances in Clinical Study of Curcumin
Current Pharmaceutical Design Pharmacotherapy for Obesity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Homodimeric Enzymes as Drug Targets
Current Medicinal Chemistry Anti-Neuroinflammatory Properties of n-3 Fatty Acids and Nano- Curcumin on Migraine Patients from Cellular to Clinical Insight: A Randomized, Double-Blind and Placebo-Controlled Trial
Endocrine, Metabolic & Immune Disorders - Drug Targets Preface [Hot Topic: Rational Drug Design and The Discovery of the 1,2,3-Triazolines as a Unique Class of Anticonvulsants and Antiischemic Agents (Guest Editor: Pankaja K. Kadaba)]
Current Medicinal Chemistry Do Folate, Vitamins B<sub>6</sub> and B<sub>12</sub> Play a Role in the Pathogenesis of Migraine? The Role of Pharmacoepigenomics
CNS & Neurological Disorders - Drug Targets Integrated UPLC-MS/MS and UHPLC-Q-orbitrap HRMS Analysis to Reveal Pharmacokinetics and Metabolism of Five Terpenoids from <i>Alpiniae oxyphyllae</i> Fructus in Rats
Current Drug Metabolism Third Generation Antipsychotic Drugs: Partial Agonism or Receptor Functional Selectivity?
Current Pharmaceutical Design